Targeting Hypoxia-Inducible Factor in the Management of Anemia in Patients with CKD: An Update on Emerging Therapies – February 16

Join us for an interactive CME Webinar!

 

Tuesday, February 16, 2021
8:00 PM – 9:00 PM (ET)

 

PROGRAM OVERVIEW

Patients with chronic kidney disease (CKD) and anemia experience substantially increased burdens to morbidity and mortality. Erythropoiesis-stimulating agents (ESA) and iron supplementation are mainstays of therapy, yet ESA has been associated with increased cardiovascular adverse events. Increased understanding of hypoxia-inducible factors (HIFs) has led to the development of novel therapies, hypoxia-iducible factor prolyl hydroxylase inhibitors (HIF-PHIs) that work by simulating hypoxia in cells, thereby stimulating EPO synthesis and improving iron metabolism and mobilization through reduced hepcidin levels.

Three HIF-PHIs (i.e. roxadustat, vadadustat, and daprodustat) are currently undergoing late-stage development, with one agent already approved to treat anemia in patients with CKD in China. To be best prepared to incorporate these agents into clinical practice once FDA-approved, nephrologists must be educated on the pathophysiological mechanisms involved in CKD-related anemia and recent outcomes from clinical trials evaluating these agents in patients with CKD. This educational activity will address these knowledge gaps among nephrologists, and application of this knowledge will improve outcomes for patients with anemia and CKD.

FACULTY

 

Anil K. Agarwal, MD, FASN
Professor of Medicine
University of California, San Francisco
Fresno School of Medicine
Fresno, California

TARGET AUDIENCE

This educational activity is intended for nephrology fellows, attendings, and trainees.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Summarize the prevalence of and burden associated with anemia in patients with CKD, particularly those who are hyporesponsive to ESA therapy
  • Articulate the pathogenic mechanisms involved in anemia associated with CKD, including the roles of inflammation, hepcidin, and the HIF pathway
  • Interpret outcomes from clinical trials evaluating the use of HIF-PHIs to treat anemia in patients with CKD
  • Review the potential place of HIF-PHIs in the management of anemia in patients with CKD

PHYSICIAN CONTINUING MEDICAL EDUCATION ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must view the webinar, participate in program polling questions, and complete the evaluation form at the end of the program. A statement of credit will be issued only upon submission of a completed activity evaluation form and will be sent to you within four weeks of receipt of the completed evaluation.

FEE INFORMATION

There is no fee for this educational activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST (COI)

Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Anil K. Agarwal, MD, FASN
Consulting Fees: AstraZeneca, Otsuka
Speakers’ Bureaus: AstraZeneca, Janssen
Contracted Research: CordMedix, Inc.

Integrity Continuing Education planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from AstraZeneca.

 

Agenda

Click on the link below to access the webinar on the day of the event.
www.integrityce.com/CKD-2